China Pharma Holdings, Inc. — Q2 2022 Form 10-Q
Business context and reporting period. The company develops, manufactures, and markets prescription pharmaceuticals in China through its PRC subsidiary. This unaudited filing covers the three and six months ended June 30, 2022; comparisons are with the corresponding 2021 periods. All figures are in U.S. dollars unless stated otherwise.
Key financial results
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $1.613 million | $2.416 million | $3.217 million | $4.774 million |
| Gross profit (loss) | $(0.229) million | $0.071 million | $(0.399) million | $0.344 million |
| Gross margin | (14.2%) | 2.9% | (12.4%) | 7.2% |
| Operating loss | $(0.780) million | $(0.753) million | $(1.691) million | $(1.449) million |
| Net loss | $(0.888) million | $(0.825) million | $(1.918) million | $(1.592) million |
| Basic and diluted loss per share | $(0.02) | $(0.02) | $(0.04) | $(0.03) |
Cash flow and liquidity. For the first half, operating activities used $1.213 million, investing activities used $0.177 million (mainly equipment purchases), and financing activities used $1.126 million. Cash declined $2.614 million to $2.245 million at June 30, 2022. Current assets were $6.259 million versus current liabilities of $8.361 million. Management says all cash is held in the Chinese subsidiary and is not expected to be available for parent-company or shareholder payments.
Debt and balance sheet. At June 30, current lines of credit totaled $3.233 million, related-party borrowings were $2.502 million, and the convertible redeemable note was $4.750 million. The note bears 5% interest, matures 15 months after funding, and is subject to investor redemption and conversion provisions. Stockholders’ equity was $4.025 million; accumulated deficit was $34.157 million. Net trade receivables were $0.319 million after a $17.385 million allowance against gross receivables. Inventory was $3.530 million.
Material changes and management commentary
- Revenue fell 33.2% in Q2 and 32.6% in the first half. Management attributed the decline to lower prices under China’s centralized drug procurement program and COVID-related quarantine, logistics disruption, and drug-sales controls. First-half declines were concentrated in Anti-Viral/Infection & Respiratory and CNS/Cerebral & Cardiovascular products.
- Cost of revenue exceeded sales: 114.2% of revenue in Q2 and 112.4% for the first half, compared with 97.1% and 92.8% a year earlier. Management cited fixed costs that did not fall with revenue. The company moved from gross profit to gross loss in both comparison periods.
- First-half selling and R&D expenses decreased year over year, while general and administrative expenses rose. Interest expense also increased. Although MD&A says the first-half net loss “decreased,” the financial statements show it increased to $1.918 million from $1.592 million.
- The company disclosed substantial doubt about its ability to continue as a going concern within one year after issuance of the financial statements. Management cited continuing operating losses, debt service, and limited liquidity. Its proposed mitigations include greater use of advance payments, stronger receivables collection, pursuing nutrition-product opportunities, and using fixed assets to support additional borrowing; plans were not finalized and their implementation is not assured.
- Lines of credit have near-term maturities, including amounts due in 2022. Management said it did not expect difficulty refinancing, but warned that financing may not be available on acceptable terms. The CEO/CFO advanced $1.147 million at quarter-end; future support is not assured.
- The convertible note permits monthly redemptions, generally at 85% of the lowest volume-weighted average share price over a specified period. Redemptions converted into 1,970,515 shares during the first half. After quarter-end, a further $200,000 redemption resulted in 1,139,601 shares issued on August 4, 2022. Potential dilution is significant and depends on share price and note terms.
- Risks include concentrated customers, suppliers, and products; three customers represented 53.3%, 11.5%, and 10.4% of receivables. The filing reports 98.1% of receivables in the over-720-day aging category, alongside a large allowance. Operations and revenue are concentrated in China, with RMB conversion and remittance controls and potential COVID-related disruption.
- Disclosure controls were deemed ineffective because of a material weakness involving insufficient personnel knowledgeable in U.S. GAAP. Management nevertheless stated that the interim statements were fairly stated in all material respects. The company reported no off-balance-sheet arrangements.
Important facts for investors to verify
- Whether management’s liquidity and going-concern plans are implemented, and whether additional financing or debt refinancing is secured.
- Near-term repayment or refinancing status of lines of credit and the terms, maturity, and redemption activity of the convertible note.
- Subsequent share issuance, current share count, and potential dilution from the note’s price-based conversion provisions.
- Receivables collectability, the very aged receivables balance, customer concentration, and adequacy of the doubtful-account allowance.
- Progress on drug consistency evaluation, centralized-procurement exposure, and any concrete nutrition-product launch plans; the filing provides no quantified earnings or revenue guidance.
- Remediation of the material weakness in financial reporting controls and the effects of China-related operating, currency, and remittance risks.